Semaglutide is safe, not just for obese patients, and it wasnt designed for you to use indefinitely
While it works, the fractional units make accurate drawing more difficult
In semaglutides case: Novo Nordisk obtained a genus patent covering semaglutide as a compound, with the usual 20year protection.[19][20] Later, it filed a second patent on a closely related version intended to prolong exclusivity, along with a series of secondary patents on formulations and delivery devices.[21][14] The Delhi High Court, examining Novos suit against Indian companies like Dr Reddys, held that this second patent amounted to double patenting and evergreening , which is barred under Indias Patents Act (Section 3(d)).[20][22][19] Because India explicitly prohibits evergreening, the court refused to block Indian firms from manufacturing and exporting semaglutide while maintaining restrictions on incountry sales tied to remaining patent issues.[23][20] Key point: Courts in India have openly described parts of Novos semaglutide strategy as evergreeningextending monopoly protection beyond what a single invention normally deserves
Heres where things get interesting
These are standard practices for all peptide users, but the consequences of contamination are more severe for autoimmune patients
